Leukemia and Lymphoma

SJR Rank #6,182H-index: 109SJR: 0.861Best quartile: Q2
Journal website: aims, scope and author guidelines
Publisher

Taylor and Francis Ltd.

Country

United Kingdom

Type

journal

SJR by Edition

2022202500.250.50.751

Subject Categories

  • HematologyQ2
  • OncologyQ2
  • Cancer ResearchQ3

Areas: Biochemistry, Genetics and Molecular Biology · Medicine

Most published research topics

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchAcute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia researchViral-associated cancers and disordersChronic Myeloid Leukemia TreatmentsMultiple Myeloma Research and TreatmentsHematopoietic Stem Cell TransplantationCNS Lymphoma Diagnosis and TreatmentMyeloproliferative Neoplasms: Diagnosis and Treatment

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs03006009001200

Documents per Year

202220250150300450600

Detailed Information

ISSN

1029-2403, 1042-8194

SJR Best Quartile

Q2

Region

Western Europe

Citations per Document (2 years)

1.64

References per Document

34.96

Coverage

1989-2026

Scope

Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor. Leukemia & Lymphoma is also dedicated to education in the form of reviews, commentaries, conference summaries and emerging drug profiles. All submissions are subject to peer review and disclosure requirements, as stipulated by the International Committee of Medical Journal Editors (ICMJE). Rapid turnaround time for reviews as well as fast online publication assure timely access to accepted publications. The journal provides a premier reference source for physicians and scientists interested in clinical, translational, and laboratory research, as well as clinical diagnosis and treatment of patients with malignant hematological disorders.

Metrics from SCImago Journal Rank 2025. View on SCImago